These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37243674)

  • 1. Identifying potentially undiagnosed nontuberculous mycobacterial lung disease among patients with chronic obstructive pulmonary disease: Development of a predictive algorithm using claims data.
    Wang P; Marras TK; Allison PD; Hassan M; Chatterjee A
    J Manag Care Spec Pharm; 2023 Aug; 29(8):927-937. PubMed ID: 37243674
    [No Abstract]   [Full Text] [Related]  

  • 2. Incremental mortality associated with nontuberculous mycobacterial lung disease among US Medicare beneficiaries with chronic obstructive pulmonary disease.
    Wang P; Marras TK; Hassan M; Chatterjee A
    BMC Infect Dis; 2023 Nov; 23(1):749. PubMed ID: 37914999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health Care Utilization and Expenditures Following Diagnosis of Nontuberculous Mycobacterial Lung Disease in the United States.
    Marras TK; Mirsaeidi M; Chou E; Eagle G; Zhang R; Leuchars M; Zhang Q
    J Manag Care Spec Pharm; 2018 Oct; 24(10):964-974. PubMed ID: 30028225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and Validation of a Predictive Model to Identify Individuals Likely to Have Undiagnosed Chronic Obstructive Pulmonary Disease Using an Administrative Claims Database.
    Moretz C; Zhou Y; Dhamane AD; Burslem K; Saverno K; Jain G; Devercelli G; Kaila S; Ellis JJ; Hernandez G; Renda A
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1149-59. PubMed ID: 26679964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative risk of all-cause mortality in patients with nontuberculous mycobacterial lung disease in a US managed care population.
    Marras TK; Vinnard C; Zhang Q; Hamilton K; Adjemian J; Eagle G; Zhang R; Chou E; Olivier KN
    Respir Med; 2018 Dec; 145():80-88. PubMed ID: 30509721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guidelines-based treatment associated with improved economic outcomes in nontuberculous mycobacterial lung disease.
    Marras TK; Mirsaeidi M; Vinnard C; Chan ED; Eagle G; Zhang R; Wang P; Zhang Q
    J Med Econ; 2019 Nov; 22(11):1126-1133. PubMed ID: 31094592
    [No Abstract]   [Full Text] [Related]  

  • 7. Identification of potentially undiagnosed patients with nontuberculous mycobacterial lung disease using machine learning applied to primary care data in the UK.
    Doyle OM; van der Laan R; Obradovic M; McMahon P; Daniels F; Pitcher A; Loebinger MR
    Eur Respir J; 2020 Oct; 56(4):. PubMed ID: 32430411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spirometry evaluation to assess performance of a claims-based predictive model identifying patients with undiagnosed COPD.
    Moretz C; Annavarapu S; Luthra R; Goldfarb S; Renda A; Shaikh A; Kaila S
    Int J Chron Obstruct Pulmon Dis; 2019; 14():439-446. PubMed ID: 30863044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival associated with chronic obstructive pulmonary disease among SEER-Medicare beneficiaries with non-small-cell lung cancer.
    Shah S; Blanchette CM; Coyle JC; Kowalkowski M; Arthur ST; Howden R
    Int J Chron Obstruct Pulmon Dis; 2019; 14():893-903. PubMed ID: 31118599
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterol.
    Sethi S; Palli SR; Bengtson LGS; Buysman EK; Clark B; Sargent A; Shaikh A; Ferguson GT
    J Manag Care Spec Pharm; 2023 Jul; 29(7):791-806. PubMed ID: 37133429
    [No Abstract]   [Full Text] [Related]  

  • 11. Development and validation of a drug adherence index for COPD.
    Bengtson LGS; Bancroft T; Schilling C; Buikema AR; Stanford RH
    J Manag Care Spec Pharm; 2021 Feb; 27(2):198-209. PubMed ID: 33506734
    [No Abstract]   [Full Text] [Related]  

  • 12. External Validation of a COPD Risk Measure in a Commercial and Medicare Population: The COPD Treatment Ratio.
    Stanford RH; Lau MS; Li Y; Stemkowski S
    J Manag Care Spec Pharm; 2019 Jan; 25(1):58-69. PubMed ID: 30589629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-tuberculous mycobacterial lung disease (NT MLD ) in patients with chronic thromboembolic pulmonary hypertension and idiopathic pulmonary arterial hypertension.
    Wilińska E; Oniszh K; Augustynowicz-Kopeć E; Zabost A; Fijałkowska A; Kurzyna M; Wieteska M; Torbicki A; Kuś J; Szturmowicz M
    Pneumonol Alergol Pol; 2014; 82(6):495-502. PubMed ID: 25339559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An algorithm for the identification of undiagnosed COPD cases using administrative claims data.
    Mapel DW; Frost FJ; Hurley JS; Petersen H; Roberts M; Marton JP; Shah H
    J Manag Care Pharm; 2006; 12(6):457-65. PubMed ID: 16925453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting Acute Exacerbations in Chronic Obstructive Pulmonary Disease.
    Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA
    J Manag Care Spec Pharm; 2018 Mar; 24(3):265-279. PubMed ID: 29485951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The clinical analysis of chronic obstructive pulmonary disease patients complicated with nontuberculous mycobacterial pulmonary disease].
    Sun YX; Shao C; Li S; Xu K; Huang H; Xu ZJ
    Zhonghua Jie He He Hu Xi Za Zhi; 2019 Nov; 42(11):826-831. PubMed ID: 31694092
    [No Abstract]   [Full Text] [Related]  

  • 17. Nontuberculous mycobacterial lung disease in a high tuberculosis incidence setting in Brazil.
    Carneiro MDS; Nunes LS; David SMM; Dias CF; Barth AL; Unis G
    J Bras Pneumol; 2018 Apr; 44(2):106-111. PubMed ID: 29791549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Healthcare utilization and costs associated with COPD among SEER-Medicare beneficiaries with NSCLC.
    Shah S; Blanchette CM; Coyle JC; Kowalkowski M; Arthur ST; Howden R
    J Med Econ; 2018 Sep; 21(9):861-868. PubMed ID: 29857784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of compliance with GOLD treatment recommendations on COPD health care resource utilization, cost, and exacerbations among patients with COPD on maintenance therapy.
    Palli SR; Zhou S; Shaikh A; Willey VJ
    J Manag Care Spec Pharm; 2021 May; 27(5):625-637. PubMed ID: 33779246
    [No Abstract]   [Full Text] [Related]  

  • 20. Hospitalization Risk for Medicare Beneficiaries With Nontuberculous Mycobacterial Pulmonary Disease.
    Prevots DR; Marras TK; Wang P; Mange KC; Flume PA
    Chest; 2021 Dec; 160(6):2042-2050. PubMed ID: 34314672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.